Indoco Remedies Ltd has received a Certificate of EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant II. The certification confirms that the site, located at Verna Industrial Estate, South Goa, meets the stringent GMP standards set by European regulators.
The announcement was made via a stock exchange filing on July 24, 2025, with the company stating that the recognition reaffirms its commitment to quality and global compliance.
Commenting on the milestone, Aditi Panandikar, Managing Director of Indoco Remedies, said, “This GMP certification for our sterile drug product manufacturing facility is a testament to our relentless efforts to supply quality and affordable medicines across geographies. We remain fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide.”
The Goa Plant II is part of Indoco’s network of 11 manufacturing units, which include seven facilities for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs). These are backed by a modern R&D centre and CRO (Contract Research Organisation) facilities. The company has a significant international footprint, supported by regulatory approvals from bodies such as the USFDA and UK-MHRA.
Indoco Remedies, a research-driven pharmaceutical firm with a turnover of $180 million, serves both domestic and international markets. Its strong domestic portfolio includes brands like Cyclopam, Febrex Plus, Sensodent-K, and Karvol Plus, among others.
The EU GMP certification is expected to enhance Indoco’s export potential, especially for its sterile product offerings in regulated European markets.
